Page 223 - 2019_07 resto del Mondo-web

Anticoagulation duration after deep-vein thrombosis
13. Schulman S, Kearon C, Kakkar AK, et al. RE- MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabiga- tran, warfarin, or placebo in venous throm- boembolism. N Engl J Med. 2013;368(8): 709-718.
14. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treat- ed for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589.
15. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagu- lant treatment and initial presentation of venous thromboembolism on risk of recur- rence after stopping treatment: analysis of individual participants' data from seven tri- als. BMJ. 2011;342:d3036.
16. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279(6):458- 462.
17. Lecumberri R, Alfonso A, Jiménez D, et al. RIETE Investigators. Dynamics of case- fatalilty rates of recurrent thromboem-
bolism and major bleeding in patients treat- ed for venous thromboembolism. Thromb Haemost. 2013;110(4):834-843.
18. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998;128(8):663-677. Erratum in: Ann Intern Med. 1998;129(5):425.
19. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):1037-1052.
20. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. 2008;359(26):2804-2813.
21. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
22. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant ther- apy. Thromb Haemost. 1993;69(3):236-239.
23. Mismetti P, Baud JM, Becker F, et al. Agence
française de sécurité sanitaire des produits de santé. [Guidelines for good clinical prac- tice: prevention and treatment of venous thromboembolism in medical patients]. J Mal Vasc. 2010;35(3):127-136.
24. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122(5):817-824.
25. Baglin T, Bauer K, Douketis J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep-vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2012;10(4):698-702.
26. Kearon C, Akl EA. Duration of anticoagulant therapy for deep-vein thrombosis and pul- monary embolism. Blood. 2014;123(12): 1794-801.
27. Rodger MA, Le Gal G, Anderson DR, et al. REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospec- tive cohort management study. BMJ. 2017;356:j1065.
haematologica | 2019; 104(7)
1501